Phase II study of personalized titration of axitinib using therapeutic drug monitoring (TDM) in sunitinib-refractory metastatic or advanced renal cell carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2017
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 18 Feb 2017 Primary endpoint (Progression-free survival rate) has been met.
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
- 01 Feb 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.